EDC3 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Homo sapiens 786-O renal cell adenocarcinoma cell line. The product consists of a heterogeneous pool of cells carrying targeted disruption of the EDC3 gene, achieved through CRISPR/Cas9-mediated gene editing. This polyclonal format provides a robust loss-of-function model for studying the enhancer of mRNA decapping 3 (EDC3) and its role in post-transcriptional gene regulation, without clonal selection artifacts. The knockout population is intended for use in a variety of functional assays to interrogate mRNA decay mechanisms and P-body dynamics in a clear cell renal cell carcinoma (ccRCC) context.
The parental 786-O cell line was originally established from a primary clear cell renal cell adenocarcinoma and serves as a widely used model for kidney cancer research. These epithelial cells exhibit characteristic features of ccRCC, including constitutive activation of hypoxia-inducible factor pathways, and are employed extensively to investigate tumor biology, therapeutic responses, and metastatic progression. The 786-O background thus provides a clinically relevant system for examining how alterations in mRNA turnover impact ccRCC pathophysiology.
EDC3 operates as a scaffold protein that enhances the activity of the DCP1-DCP2 decapping complex, a critical step in the 5??-to-3?? mRNA decay pathway. It interacts with DCP1A, DCP2, DDX6, PATL1, the LSM1-7 complex, and HPat to promote removal of the 5?? cap from target transcripts, facilitating subsequent exonucleolytic degradation by XRN1. EDC3 is regulated by upstream stress signals, including mTOR kinase, MAP kinases, reactive oxygen species, and osmotic or oxidative stress, and preferentially modulates the stability of AU-rich element (ARE)-containing mRNAs such as TNF, IL-8, c-FOS, and c-MYC. Its function is integrated within broader mRNA surveillance networks, including nonsense-mediated decay and the CCR4-NOT and PAN2-PAN3 deadenylation complexes.
In the 786-O ccRCC model, loss of EDC3 function disrupts the normal decay of short-lived transcripts, leading to stabilization of ARE-containing mRNAs that encode factors implicated in cell proliferation, inflammation, and stress adaptation. This perturbation allows researchers to dissect the contribution of EDC3-dependent mRNA turnover to renal cancer cell behavior, including growth, survival, and response to chemotherapeutic or targeted agents. The polyclonal knockout population reflects the heterogeneous nature of tumors and avoids biases introduced by single-cell cloning, making it particularly suitable for studies in which maintenance of genetic diversity is desirable.
This product supports a range of downstream applications, including RNA stability assays such as actinomycin D chase experiments, RT-qPCR measurements of target mRNA half-lives, western blotting to confirm EDC3 loss, and immunofluorescence analysis of P-body formation and composition. RNA-sequencing can uncover transcriptome-wide changes resulting from impaired decapping, while co-immunoprecipitation experiments enable characterization of residual decapping complexes. Functional assays evaluating cell proliferation, migration, and invasion further contextualize the impact of EDC3 knockout in ccRCC. For further information or to discuss custom applications, please contact Ascent Research.
